Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines.
Analgesics
Anesthetics
Antimicrobials
Mucosal coating agents
Oral mucositis
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
02
10
2019
accepted:
07
11
2019
pubmed:
14
2
2020
medline:
17
6
2020
entrez:
14
2
2020
Statut:
ppublish
Résumé
To update the clinical practice guidelines for the use of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the prevention and/or treatment of oral mucositis (OM). A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the 2014 MASCC/ISOO clinical practice guidelines. Based on the evidence level, the following guidelines were determined: Recommendation, Suggestion, and No Guideline Possible. A total of 9 new papers were identified within the scope of this section, adding to the 62 papers reviewed in this section previously. A new Suggestion was made for topical 0.2% morphine for the treatment of OM-associated pain in head and neck (H&N) cancer patients treated with RT-CT (modification of previous guideline). A previous Recommendation against the use of sucralfate-combined systemic and topical formulation in the prevention of OM in solid cancer treatment with CT was changed from Recommendation Against to No Guideline Possible. Suggestion for doxepin and fentanyl for the treatment of mucositis-associated pain in H&N cancer patients was changed to No Guideline Possible. Of the agents studied for the management of OM in this paper, the evidence supports a Suggestion in favor of topical morphine 0.2% in H&N cancer patients treated with RT-CT for the treatment of OM-associated pain.
Identifiants
pubmed: 32052137
doi: 10.1007/s00520-019-05181-6
pii: 10.1007/s00520-019-05181-6
doi:
Substances chimiques
Analgesics
0
Anesthetics
0
Anti-Infective Agents
0
Antineoplastic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2473-2484Références
Pain. 2003 Sep;105(1-2):265-73
pubmed: 14499444
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):479-85
pubmed: 12243825
Cancer. 2001 Aug 15;92(4):875-85
pubmed: 11550161
Dent Clin North Am. 2008 Jan;52(1):61-77, viii
pubmed: 18154865
J Palliat Med. 2007 Oct;10(5):1063-7
pubmed: 17985962
J Clin Oncol. 2014 May 20;32(15):1571-7
pubmed: 24733799
Radiother Oncol. 1998 May;47(2):149-53
pubmed: 9683362
N Engl J Med. 1995 Jun 22;332(25):1685-90
pubmed: 7760870
Drug Des Devel Ther. 2014 May 12;8:497-503
pubmed: 24872680
Support Care Cancer. 2007 Apr;15(4):427-40
pubmed: 17131132
J Clin Epidemiol. 1996 Jul;49(7):749-54
pubmed: 8691224
Support Care Cancer. 2015 Mar;23(3):753-9
pubmed: 25179692
Support Care Cancer. 2003 Jan;11(1):41-7
pubmed: 12527953
Nat Rev Cancer. 2004 Apr;4(4):277-84
pubmed: 15057287
Aust Nurs J. 2009 Apr;16(9):30-3
pubmed: 19437954
Am J Med. 1991 Aug 8;91(2A):158S-160S
pubmed: 1715670
Oral Oncol. 2000 Jan;36(1):116-20
pubmed: 10889930
Cancer Invest. 2003;21(1):21-33
pubmed: 12643006
Support Care Cancer. 2013 Nov;21(11):3191-207
pubmed: 23832272
J Clin Oncol. 1997 Mar;15(3):1235-8
pubmed: 9060567
Acta Oncol. 1990;29(4):471-3
pubmed: 2390274
Bone Marrow Transplant. 2004 Jun;33(12):1247-51
pubmed: 15094750
Transplant Proc. 2005 Dec;37(10):4488-91
pubmed: 16387151
Onco Targets Ther. 2018 Nov 30;11:8555-8564
pubmed: 30584316
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Oncol Rep. 2000 May-Jun;7(3):659-61
pubmed: 10767386
Expert Opin Pharmacother. 2008 Dec;9(18):3137-44
pubmed: 19040334
Acta Oncol. 1995;34(2):219-23
pubmed: 7718260
Pain. 1999 Mar;80(1-2):121-5
pubmed: 10204724
Adv Biomed Res. 2015 Feb 11;4:44
pubmed: 25789270
Oral Oncol. 2014 Sep;50(9):884-7
pubmed: 25001894
Int J Radiat Oncol Biol Phys. 1994 Feb 1;28(3):693-8
pubmed: 8113113
Pain Rep. 2017 Aug 23;2(5):e619
pubmed: 29392234
Cancer. 2002 Nov 15;95(10):2230-6
pubmed: 12412178
Pharmacol Rev. 2018 Apr;70(2):197-245
pubmed: 29487083
Head Neck. 1999 Dec;21(8):760-6
pubmed: 10562690
Spec Care Dentist. 2008 Mar-Apr;28(2):73-7
pubmed: 18402621
Tumori. 1996 Nov-Dec;82(6):585-7
pubmed: 9061069
Support Care Cancer. 2015 Feb;23(2):359-64
pubmed: 25084742
Pract Radiat Oncol. 2013 Jul-Sep;3(3):229-233
pubmed: 24674369
Support Care Cancer. 2019 Oct;27(10):3933-3948
pubmed: 31286227
Nutr Cancer. 2016;68(3):456-63
pubmed: 27007594
J Pediatr. 1988 Oct;113(4):758-63
pubmed: 3050005
N Engl J Med. 1991 Oct 3;325(14):1017-25
pubmed: 1886624
Acta Oncol. 2001;40(6):751-5
pubmed: 11765071
Cancer. 2004 May 1;100(9 Suppl):2026-46
pubmed: 15108223
J Oncol Pharm Pract. 2019 Mar;25(2):409-422
pubmed: 29460703
Eur J Cancer Care (Engl). 2008 May;17(3):270-7
pubmed: 18419630
Support Care Cancer. 2006 Jan;14(1):44-51
pubmed: 15947956
Med Sci Monit. 2011 Oct;17(10):CR572-6
pubmed: 21959611
J Clin Gastroenterol. 1999 Jan;28(1):40-3
pubmed: 9916664
Cancer. 2014 May 1;120(9):1433-40
pubmed: 24877167
Am J Med. 1989 Jun 9;86(6A):23-31
pubmed: 2735333
J Exp Ther Oncol. 1996 Mar;1(2):135-8
pubmed: 9414397
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):177-82
pubmed: 8083112
Ann Oncol. 2001 Jul;12(7):953-5
pubmed: 11521801
Eur J Pharmacol. 2013 Sep 15;716(1-3):106-19
pubmed: 23500198
Anticancer Res. 2001 Sep-Oct;21(5):3707-10
pubmed: 11848548
Oral Surg Oral Med Oral Pathol. 1991 Mar;71(3):288-93
pubmed: 1707149
Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):275-9
pubmed: 9069297
J Palliat Med. 2010 Feb;13(2):125-8
pubmed: 19827964